Baxdela

The FDA has approved Baxdela, a drug intended to treat adults with acute bacterial skin and skin structure infections caused by susceptible bacteria. Baxdela is also effective in treating MRSA and against other gram-positive or gram-negative pathogens.

--Melinta Therapeutics, Inc., a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced the U.S. Food and Drug Administration has approved BAXDELA for the treatm

Delafloxacin is a new fluoroquinolone antibiotic available in intravenous and oral formulations for the treatment of serious skin and skin structure infections in patients requiring initial intravenous therapy. It is effective for infections caused by MRS

The FDA recently approved an IV and oral formulation of Baxdela, an anionic fluoroquinolone, for the treatment of acute bacterial skin and skin structure infections, or ABSSSIs, including MRSA.The approval of both formulations is supported by data from tw

The FDA recently approved an IV and oral formulation of Baxdela, an anionic fluoroquinolone, for the treatment of acute bacterial skin and skin structure infections, or ABSSSIs, including MRSA. The approval of both formulations is supported by data from t

Ligand Pharmaceuticals Incorporated (LGND) said its partner Melinta Therapeutics, a private pharma company, has submitted New Drug Applications (NDAs) to the FDA for its pipeline candidate Baxdela (delafloxacin) to treat serious bacterial infections.